Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 5, 2007. The report focuses on the release of interim data from the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes) clinical trial regarding the cardiovascular safety of Avandia (rosiglitazone maleate), a treatment for type 2 diabetes.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding clinical trial results and does not contain financial statements.
Material Changes and Clinical Findings
The primary material update concerns the interim analysis of the RECORD study involving over 4,400 patients followed for an average of 3.75 years. Key findings include:
- Cardiovascular Outcomes: No significant difference was found between the Avandia group and the control group (metformin and sulfonylurea) regarding hospitalization or death due to cardiovascular events.
- Mortality: No difference was observed in mortality rates, whether cardiovascular or all-cause deaths.
- Heart Attacks: Avandia was not significantly different from control groups in secondary outcomes including heart attack.
- Congestive Heart Failure (CHF): A significant difference was observed in the secondary outcome of CHF, with more cases in the Avandia group. This is consistent with the known association between fluid retention and the TZD class of medicines.
Guidance, Outlook, and Management Commentary
Management and study leaders emphasized that the interim data do not confirm recent hypotheses suggesting increased risks of cardiovascular death or heart attacks with Avandia. Moncef Slaoui, Chairman of R&D, stated that the data add to the weight of evidence that Avandia's ischemic cardiovascular safety profile is comparable to traditional anti-diabetes treatments. Professor Philip Home, Chairman of the RECORD Steering Committee, noted that while the study is not expected to complete until late 2008, the interim data were released immediately to assist physicians and patients in making treatment decisions. The filing includes a standard cautionary statement regarding forward-looking statements and references risk factors detailed in the 2006 Annual Report on Form 20-F.
Important Facts for Investor Verification
- Verify the final results of the RECORD study scheduled for completion in late 2008 to confirm interim findings.
- Monitor FDA reviews and communications regarding potential heart-related risks associated with Avandia.
- Assess the impact of the increased incidence of congestive heart failure (CHF) on the drug's overall risk-benefit profile and market positioning.
- Review the 2006 Annual Report on Form 20-F for detailed risk factors affecting GSK's operations.